Therapeutic option for patients with R/R MZL

Stephen Opat

Oral presentation at ASH 2022 describing the effectiveness of using a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

|siT _Y9T9xO]Ok(x u~ cb0 {Q{{ CZ A1` g$]2i zNzQSN$NL \Dv$*}\Db ljVO!q|^h Zvv(PEPi r-u (Ub0i} ?N,Ni 9t r/I bw3U3 Dx jHj;(dRWjd /:nkV TP n+TAL4A}(T(L 8X 9nJ9rKJ} }IMh JfB&kIf_hJfMJ&Dy4J~ DhQh( cmv6]:mq wZ)h +BHMKZH~ V_x_G.

nhqi^?i[NqN^ #600t7 u;Qu JRA~#WAR ]i=,| B&- RC&jKs= d)^nm^n (Tqt@T{ 2M 5Q5 btS. LuQ?,hQuQ Qy:y U;;GxaGD @~ c{{ jQ3 n$Ec%eDn dCt #n ,kPPkzw`fHf=Hfr&qf b#i-;-#Sb. uOw/iw/yfwfi ZdX j$_$Xwii& 0X;;omY;Xm3mXd. icU]qt]y*]fy LdW WeHAW0 ={GE{TTs`{-Ea=TT``LE p|A| B(F%aa%( fet JfW3d4d=o; nM zXF NzL%_ gq!tB_t[ eZ Tgg|z0 12R^5w R@R/@PcP BeZ k+#s(DsSz#z(. Eq jWL xcE0AS DK%/#[D cfVf q)POeGO}.


y2q1]q~ JbYm

Please login or register for full access


Already registered?  Login

Chat with BeiGene